TCGA-44-6777-01A-11R-1858-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 85
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.600
- ANGIOGENESIS+0.530
- ALLOGRAFT_REJECTION+0.510
- INFLAMMATORY_RESPONSE+0.480
- KRAS_SIGNALING_UP+0.480
- COMPLEMENT+0.470
- IL6_JAK_STAT3_SIGNALING+0.470
- COAGULATION+0.430
- IL2_STAT5_SIGNALING+0.410
- INTERFERON_GAMMA_RESPONSE+0.410
Top 10 suppressed
- MYC_TARGETS_V2-0.650
- E2F_TARGETS-0.580
- G2M_CHECKPOINT-0.500
- MYC_TARGETS_V1-0.500
- DNA_REPAIR-0.400
- OXIDATIVE_PHOSPHORYLATION-0.340
- SPERMATOGENESIS-0.170
- MTORC1_SIGNALING-0.070
- UNFOLDED_PROTEIN_RESPONSE-0.070
- FATTY_ACID_METABOLISM-0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CR-7386-01A-11R-2016-07 | — | — | 0.962 |
| 2 | TCGA-46-3766-01A-01R-0980-07 | — | cohortSQ1 | 0.942 |
| 3 | TCGA-38-4627-01A-01R-1206-07 | — | cohortA1 | 0.936 |
| 4 | BS_52426AMF | low-grade glioma | — | 0.936 |
| 5 | TCGA-64-5815-01A-01R-1628-07 | — | cohortA1 | 0.936 |
| 6 | TCGA-AO-A03U-01B-21R-A10J-07 | — | D | 0.931 |
| 7 | BS_RRAEQZ97 | pilocytic astrocytoma | — | 0.929 |
| 8 | TCGA-DK-A1AF-01A-11R-A13Y-07 | — | — | 0.924 |
| 9 | TCGA-73-4658-01A-01R-1755-07 | — | cohortA1 | 0.921 |
| 10 | TCGA-49-6744-01A-11R-1858-07 | — | cohortA1 | 0.915 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.600 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.530 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.510 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.480 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.480 | Inavolisib | — uncovered |
| COMPLEMENT | 0.470 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.470 | Inavolisib | — uncovered |
| COAGULATION | 0.430 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.410 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.410 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.410 | Remibrutinib | — uncovered |
| HYPOXIA | 0.400 | Idelalisib | — uncovered |
| MYOGENESIS | 0.390 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.380 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.370 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.370 | Cobimetinib | — uncovered |
| NOTCH_SIGNALING | 0.360 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.350 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.350 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.310 | Inavolisib | — uncovered |